BioCentury

7:00 AM GMT, Jul 12, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Victoza liraglutide: Extension study data

In a 26-week extension of an open-label, international Phase III trial in 658 patients inadequately controlled with metformin, 1.2 and 1.8 mg once-daily subcutaneous Victoza led to

Read the full 273 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.